ArticleSouthern African journal of HIV medicine2025
Hepatitis B seroprevalence among HIV-positive adults in the Free State, South Africa.
Article in Southern African journal of HIV medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Atypical hepatitis B surface antigen escape mutations in an HIV-positive patient in South Africa.Southern African journal of infectious diseases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HIV and hepatitis B virus (HBV) coinfection impacts negatively on the prognosis for people living with HIV (PLHIV). HBV is relatively neglected compared to HIV in the South African setting, with limited coinfection seroprevalence data from the Free State. Objectives: This study aimed to determine the seroprevalence of current and previous HBV in PLHIV in the Free State, South Africa. Method: In this descriptive cross-sectional study, 1007 residual HIV viral load (VL) samples were selected and screened for markers of current HBV infection (hepatitis B surface antigen [HBsAg]) and previous exposure to HBV (total antibodies to hepatitis B core antigen [HBcTA]) between 01 February 2022 and 31 March 2022. Seroprevalence was assessed for municipal health districts, age, sex, and HIV VL categories. Results: HBsAg seroprevalence was 6.26% and HBcTA seroprevalence was 36.05%. HBsAg seroprevalence was significantly higher in men at 8.12% as compared to women at 4.38% ( Conclusion: These findings demonstrate that PLHIV in the Free State, South Africa, fall under the intermediate HBV prevalence category. HBV infection remains a public health concern and emphasis should be placed on identifying and addressing programmatic gaps regarding diagnosis and management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.